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The clinical epidemiology of pneumonia in hemodialysis
patients has received little attention. We linked the
retrospective Waves 1, 3, and 4 Dialysis Morbidity and
Mortality Study data sets (n¼ 10 635) to Medicare claims to
identify hospitalizations with pneumonia. Mean patient age
was 60.3 years and duration of end-stage renal disease
(ESRD) 3.8 years; 41.1% of patients had diabetes mellitus.
Only 31.6% had received influenza vaccination in the 4
months preceding the study start date (January 1, 1994). The
cumulative probability of pneumonia hospitalization was
0.09 at 1 year and 0.36 at 5 years. The main associations of
hospitalization with pneumonia were age 45–64 years and
X65 years (adjusted hazards ratio (AHR) 1.26 and 1.48 vs
o45 years), chronic lung disease (AHR 1.62), ESRD duration
X10 years (AHR 0.75 vs o5 years), body mass index (AHR
0.66 for 25.0–29.9, 0.58 for X30 vs o18.5 kg/m2), serum
albumin (AHR 0.74 for X4.06 vs p3.42), and transplantation
as a time-dependent covariate (AHR 0.68). One- and 5-year
post-pneumonia survival probabilities were 0.55 and 0.17
(vs 0.76 and 0.29 in the overall study population). Adjusted
mortality hazards ratios were 4.08 (95% confidence interval
(CI) 3.41–4.89) for the 0- to 6-month interval after pneumonia,
3.04 (95% CI 2.58–3.66) for 6- to 12-months, and 2.31 (95% CI
1.97–2.71) for 12–18 months, and remained approximately
twofold thereafter. Hospitalization with pneumonia is
common in hemodialysis patients and carries a poor
prognosis.
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Registry studies typically rank infection second to cardio-
vascular disease as a cause of death in dialysis populations,
and approximately one in every five infectious deaths is
attributed to pulmonary causes.1 It has been estimated that
mortality rates from pulmonary infections in dialysis patients
are 14–16 times higher than in the general population.2 Thus,
pulmonary infections may contribute to the sizeable
morbidity and mortality of dialysis patients. In the US, for
example, some estimates suggest that pulmonary infections
account for up to 115 hospital admissions per 1000 patient-
years at risk in hemodialysis patients.1 Another study
suggested that nosocomial infections, including pneumonia,
are approximately two times more common than expected in
hospitalized hemodialysis patients.3 The ability of dialysis
patients to combat infection may be impaired by the chronic
uremic milieu as well as by age and multiple comorbid
conditions.4 It is surprising, then, that the clinical epidemio-
logy of pneumonia in dialysis patients has received compara-
tively little research attention. For example, a PubMed search
performed on March 6, 2006, using the terms maintenance
dialysis and cardiovascular yielded 494 citations. In contrast,
only 14 citations were found when pneumonia was sub-
stituted for cardiovascular. To the best of our knowledge, few
if any studies have attempted to estimate the incidence, risk
factors, and prognosis of pneumonia in dialysis patients.
The objectives of this study were to define the clinical
epidemiology of pneumonia in hemodialysis patients.
Specifically, we wished to define: (1) cumulative pneumonia-
free survival over time, (2) microbiologic attribution of index
events, (3) antecedent associations, and (4) association with
mortality.
RESULTS
We used the Waves 1, 3, and 4 Dialysis Morbidity and
Mortality Study data set. This was a historical cohort study,
conducted by the United States Renal Data System (USRDS),
of a random sample of one of every five US hemodialysis
patients alive on December 31, 1993, from more than 1300
dialysis units, with data abstraction performed retrospectively
in 1995. The original database included 16 733 patients. We
excluded patients with any of the following: absence of a
unique USRDS identification number, absence of a recorded
date of birth, date of death recorded before the study start
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date, absence of Medicare Part A as primary coverage, and
date of first end-stage renal disease (ESRD) service day less
than 90 days before December 31, 1993. This strategy
produced a final sample size of 10 635.
Table 1 shows the baseline characteristics of the study
population. The mean patient age was 60.3 years and
duration of ESRD 3.8 years; 51.1% of patients were male,
49.5% white, 24.3% had ESRD for 5 or more years, and
41.1% had diabetes mellitus as a comorbid condition. Before
the study start date of January 1, 1994, 11.3% of patients had
been waitlisted for kidney or kidney–pancreas transplants. In
the 5 years before the study start, 8.7% of patients received
vaccination for pneumonia; 9.1% of those with ESRD
duration between 5 and 10 years and 8.5% of those with
ESRD duration greater than 10 years received vaccination for
pneumonia. In the 4 months preceding the study start, 31.6%
of all patients received vaccination for influenza.
Table 1 also shows antecedent associations of hospitaliza-
tion with pneumonia for the total cohort and for the
waitlisted subset. On Cox regression, the main associations
(arbitrarily defined as an adjusted hazards ratio (AHR)
X1.25 or p0.75, Po0.01) of hospitalization with pneumo-
nia were as follows: age 45–64 years and X65 years (AHR
1.26 and 1.48 compared to age o45 years), chronic
lung disease (AHR 1.62), duration of renal replacement
therapy X10 years (AHR 0.75 compared to o5 years),
body mass index (AHR 0.66 for 25.0–29.9 kg/m2, 0.58 for
X30 kg/m2, compared to o18.5 kg/m2), serum albumin
(AHR 0.74 for X4.06 vs p3.42), and the occurrence of
transplantation during follow-up (AHR 0.68). Other associa-
tions with AHR 41.0 included smoking, cardiovascular
disease, and history of congestive heart failure. Hemoglobin
levels, creatinine levels, and cholesterol levels had associated
AHRso1.
In analyses restricted to waitlisted patients, associations of
hospitalization with pneumonia (Po0.05) included age
45–64 years and X65 years (AHR 1.50 and 2.38 compared
to age o45 years), hypertension, and diabetes as cause of
ESRD (AHR 1.53 and 1.87, respectively, compared to
glomerulonephritis as cause of ESRD), coronary artery
disease (AHR 1.32), congestive heart failure (AHR 1.39),
neoplasm (AHR 1.73), and chronic lung disease (AHR 1.63).
Over an average follow-up interval of 3.3 years, 28.9% of
the study population was hospitalized with pneumonia. The
cumulative probabilities of pneumonia hospitalization were
0.09 at 1 year and 0.36 at 5 years in the overall population,
and 0.07 at 1 year and 0.27 at 5 years for waitlisted patients
(Po0.0001 vs non-waitlisted) (Figure 1). Pneumonia was the
primary discharge diagnosis in 57.1% of all hospitalizations
involving pneumonia. When considering only those hospi-
talizations with pneumonia as the primary diagnosis, the
cumulative probability of pneumonia hospitalization was
0.06 at 1 year and 0.22 at 5 years for all patients, and 0.04 at 1
year and 0.18 at 5 years for patients on the waiting list.
Table 2 shows the associated microbiologic spectrum. No
organism was specified in 81.8% of cases, 11.1% of cases were
attributed to Gram-negative bacteria, and 4.8% were
attributed to Gram-positive bacteria.
During the index hospitalization with pneumonia, 384
(12.4%) of the 3101 patients died, 134 with a primary
diagnosis of pneumonia and 250 with a secondary diagnosis
of pneumonia. For patients with pneumonia, post-pneumo-
nia survival probabilities were 0.55 at 1 year and 0.17 at
5 years (using date of admission of first hospitalization with
pneumonia as starting point). The corresponding proba-
bilities in the waitlisted population were 0.73 and 0.44,
Po0.0001 vs non-waitlisted (Figure 2). With Poisson
regression analysis, performed in 6-month intervals, adjusted
mortality hazards ratios were 4.08 (95% confidence interval
(CI) 3.41–4.89) for the 0- to 6-month interval, 3.04 (95% CI
2.58–3.66) for the 6- to 12-month interval, and 2.31 (95% CI
1.97–2.71) for the 12- to 18-month interval (Figure 3).
Adjusted mortality hazards ratios remained approximately
equal to 2.0 for up to 8 years after hospitalization with
pneumonia. When this analysis was limited to the 1199
waitlisted patients, adjusted mortality hazards ratios were
4.19 (95% CI 1.47–11.92) for the 0- to 6-month interval, 3.65
(95% CI 1.59–8.40) for the 6- to 12-month interval, and 3.03
(95% CI 1.79–6.61) for 12- to 18-month interval (Figure 4).
DISCUSSION
We found that hospitalization with pneumonia was a
relatively common event, one experienced by approximately
one-third of dialysis patients by 5 years of follow-up. A
microbiologic diagnosis was specified in a minority of cases.
As expected, older age and comorbid diseases were associated
with a greater risk of pneumonia, and renal transplantation
was associated with lower event rates. Finally, hospitalization
with pneumonia was associated with lower survival prob-
abilities.
Pneumonia rates were higher than expected from general
population estimates. For example, a study of Medicare
patients in the US reported a hospitalized community-
acquired pneumonia rate of 18.3 per 1000 in 1997.5 This rate
was approximately one-fifth of the rate seen in our study,
even though the patients we studied were 17 years younger
on average. Tveit et al.6 reported a pneumonia rate of 2.86
episodes per 100 patient-years in kidney transplant recipi-
ents, lower than the rate of hospitalization for pneumonia as
the primary diagnosis we observed in chronic dialysis
patients waitlisted for transplantation. Pneumonia is a
frequent nosocomial infection in hemodialysis patients,
occurring at the rate of 1.7 per 1000 patient-days of
hospitalization.3
Hemodialysis patients often have nonrenal comorbid
conditions and may be susceptible to infection because the
uremic internal milieu leads to impaired chemotaxis,
adherence, reactive oxygen species production, and phago-
cytosis and accelerated apoptosis of granulocytes.4,7 Thera-
peutic immunosuppression is the cornerstone of renal
transplantation management; thus, the observation of lower
pneumonia rates after renal transplantation suggests that
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Table 1 | Antecedent associations of pneumonia in the overall population and in those waitlisted for transplant before the
study start date (11.3%)
Adjusted hazards ratios for pneumoniaa
Characteristic
% Overall
(n=10 635)
% Waitlisted
(n=1199) Overall population P
Waitlisted
population P
Age (years)
o45 19.1 49.8 1 — 1 —
45–64 35.5 44.9 1.26 (1.13, 1.41) o0.0001 1.50 (1.18, 1.91) 0.0011
X65 45.4 5.3 1.48 (1.31, 1.67) o0.0001 2.38 (1.49, 3.81) 0.0003
Race
White 49.5 48.5 1 — 1 —
African American 40.6 39.9 0.93 (0.86, 1.02) NS 1.15 (0.89, 1.49) NS
Asian 1.9 2.7 0.85 (0.65, 1.12) NS 0.46 (0.16, 1.24) NS
Native American 1.3 1.5 1.35 (1.03, 1.78) 0.0303 1.91 (0.86, 4.27) NS
Other 5.6 6.6 1.15 (0.99, 1.34) NS 1.31 (0.89, 1.93) NS
Unknown 1.1 0.9 0.80 (0.55, 1.17) NS 1.59 (0.61, 4.12) NS
Gender
Male 51.1 59.7 1 — 1 —
Female 48.9 40.3 1.02 (0.94, 1.10) NS 1.12 (0.88, 1.42) NS
Former or current smoker 33.6 32.2 1.12 (1.04, 1.22) 0.0037 1.07 (0.85, 1.35) NS
RRT duration (years)
o5 75.8 60.5 1 — 1 —
5–9.9 16.5 27.6 0.99 (0.90, 1.11) NS 0.96 (0.71, 1.28) NS
X10 7.8 11.9 0.75 (0.64, 0.89) 0.0005 0.86 (0.58, 1.28) NS
Cause of ESRD
Glomerulonephritis 14.2 26.9 1 — 1 —
Hypertension 31.1 23.4 1.08 (0.96, 1.21) NS 1.53 (1.11, 2.12) 0.0112
Diabetes mellitus 31.4 18.9 0.99 (0.86, 1.17) NS 1.87 (1.13, 3.10) 0.0148
Polycystic kidney disease 3.6 7.0 0.85 (0.69, 1.05) NS 1.15 (0.71, 1.86) NS
Urologic disease 2.0 1.6 0.96 (0.73, 1.25) NS 1.97 (0.85, 4.56) NS
Other 10.2 15.4 0.99 (0.85, 1.14) NS 1.74 (1.23, 2.46) 0.0016
Unknown or missing 7.5 6.9 0.96 (0.81, 1.13) NS 1.40 (0.87, 2.25) NS
Previous transplantation 8.3 42.2 0.98 (0.85, 1.14) NS 1.04 (0.73, 1.49) NS
Received influenza vaccine 1 September
1993 to 31 December 1993
31.6 36.5 0.93 (0.86, 1.01) NS 0.94 (0.75, 1.18) NS
Body mass index (kg/m2)
o18.5 6.2 5.3 1 — 1 —
18.5–24.9 46.3 49.3 0.80 (0.69, 0.92) 0.0023 0.69 (0.43, 1.09) NS
25.0–29.9 24.8 24.3 0.66 (0.57, 0.78) o0.0001 0.69 (0.42, 1.14) NS
X30.0 17.2 16.1 0.58 (0.49, 0.69) o0.0001 0.64 (0.38, 1.08) NS
Missing 5.6 5.1 0.91 (0.73, 1.13) NS 1.28 (0.67, 2.46) NS
Kt/V
o1.0 18.8 19.6 1 — 1 —
1.0–1.1 26.1 27.6 0.88 (0.79, 0.98) 0.0223 1.11 (0.80, 1.53) NS
1.2–1.3 22.4 21.7 0.90 (0.80, 1.01) NS 0.97 (0.68, 1.38) NS
X1.4 17.2 15.9 0.92 (0.81, 1.04) NS 0.94 (0.83, 1.06) NS
Missing 15.5 15.2 0.96 (0.84, 1.09) NS 1.22 (0.82, 1.82) NS
Albumin (g/dl)
p3.42 16.4 9.1 1 — 1 —
3.43–3.67 19.7 15.9 0.98 (0.86, 1.10) NS 0.86 (0.56, 1.33) NS
3.68–3.85 20.1 18.4 0.88 (0.78, 0.99) 0.0356 0.92 (0.60, 1.42) NS
3.86–4.05 20.3 22.5 0.81 (0.71, 0.91) 0.0008 0.78 (0.51, 1.20) NS
X4.06 18.7 29.8 0.74 (0.65, 0.85) o0.0001 0.82 (0.53, 1.24) NS
Missing 4.8 4.4 1.04 (0.81, 1.32) NS 1.35 (0.62, 2.94) NS
Hemoglobin (g/dl)
p8.80 18.6 18.0 1 — 1 —
Table 1 continued on following page
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ESRD is a state of profound immunosuppression. ESRD is
likely to be a state of inflammatory, endothelial, and redox
dysfunction. It is interesting that several characteristics
suggestive of the malnutrition–inflammation complex,8–10
such as low body mass index, low levels of serum albumin,
serum creatinine, and hemoglobin, were associated with
greater pneumonia risk in our study. Similar associations
have been found among older members of the general
population.11,12 The 6.3% of our study population receiving
renal replacement therapy for X10 years had a lower
covariate-adjusted risk of pneumonia. The reason for lower
event rates in this group is unclear, but one is tempted to
suggest that this long-term survivor cohort may be an
intrinsically healthier subgroup.
A specific microorganism was implicated in approximately
one of five cases of pneumonia in our study. Similarly, low
yields are common in general population studies and in
transplant recipients. For example, in a prospective study of
four hospitals and one health maintenance organization in
the US and Canada, only 29.7% of outpatient cases of
pneumonia had a microbiologic test, and only 5.7% had an
assigned microbiologic cause; the corresponding figures for
inpatients were 95.7 and 29.6%.13 In kidney transplant
recipients hospitalized with a primary diagnosis of pneumo-
nia, 72.5% of all cases lacked a specific microbiologic
diagnosis.6
Table 1 | Continued
Adjusted hazards ratios for pneumoniaa
Characteristic
% Overall
(n=10 635)
% Waitlisted
(n=1199) Overall population P
Waitlisted
population P
8.81–9.70 20.3 18.9 0.83 (0.74, 0.93) 0.0011 1.01 (0.71, 1.44) NS
9.71–10.40 19.1 16.8 0.87 (0.78, 0.98) 0.0208 1.10 (0.76, 1.58) NS
10.41–11.20 18.9 19.2 0.83 (0.74, 0.93) 0.0015 0.98 (0.69, 1.40) NS
X11.21 18.7 22.9 0.77 (0.68, 0.87) o0.0001 0.79 (0.55, 1.13) NS
Missing 4.3 4.2 0.78 (0.59, 1.03) NS 0.81 (0.33, 1.99) NS
Creatinine (mg/dl)
p7.3 16.3 5.2 1 — 1 —
7.4–9.2 18.6 8.6 1.07 (0.95, 1.20) NS 0.96 (0.57, 1.62) NS
9.3–11.0 19.1 16.3 0.96 (0.85, 1.09) NS 0.93 (0.58, 1.49) NS
11.1–13.4 20.0 25.5 0.82 (0.72, 0.93) 0.0024 0.66 (0.41, 1.07) NS
X13.5 19.6 38.0 0.77 (0.67, 0.89) 0.0003 0.62 (0.38, 1.01) NS
Missing 6.4 6.5 0.93 (0.74, 1.16) NS 0.42 (0.18, 0.96) 0.0399
Cholesterol (mg/dl)
p137 18.2 19.4 1 — 1 —
138–160 17.9 19.5 0.92 (0.82, 1.04) NS 0.84 (0.59, 1.19) NS
161–183 18.3 19.4 0.94 (0.84, 1.06) NS 0.99 (0.70, 1.41) NS
184–212 17.1 16.0 0.91 (0.81, 1.03) NS 0.87 (0.60, 1.26) NS
X213 16.6 14.5 0.79 (0.70, 0.90) 0.0004 0.90 (0.61, 1.33) NS
Missing 11.8 11.2 0.86 (0.74, 0.99) 0.0487 0.77 (0.49, 1.21) NS
Comorbid conditions
Diabetes mellitus 41.1 24.6 1.04 (0.92, 1.16) NS 0.91 (0.59, 1.40) NS
Coronary artery disease 38.2 22.4 1.08 (0.99, 1.18) NS 1.32 (1.01, 1.73) 0.0447
Congestive heart failure 41.6 23.9 1.23 (1.14, 1.33) o0.0001 1.39 (1.08, 1.80) 0.0116
Stroke or TIA 17.1 6.8 1.23 (1.12, 1.36) o0.0001 1.32 (0.88, 1.98) NS
Neoplasm 9.8 4.1 1.06 (0.94, 1.19) NS 1.73 (1.07, 2.79) 0.0254
PVD 25.9 12.0 0.97 (0.88, 1.06) NS 0.79 (0.54, 1.16) NS
Chronic lung disease 13.3 6.0 1.62 (1.46, 1.79) o0.0001 1.63 (1.07, 2.49) 0.0239
Follow-up
Transplantation during follow-up (time
dependent)
8.7 42.6 0.68 (0.60, 0.78) o0.0001 0.71 (0.51, 1.00) NS
ESRD, end-stage renal disease; NS, not significant; PVD, peripheral vascular disease; RRT, renal replacement therapy; TIA, transient ischemic attack.
aAdjusted hazards ratios (with 95% confidence intervals), derived from Cox regression models, adjusted for the variables shown in the first column.
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Figure 1 | Kaplan–Meier estimates of pneumonia-free survival
probabilities in non-waitlisted (solid line) and waitlisted
(dashed line) ESRD patients (Po0.0001 for non-waitlisted
vs waitlisted).
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Sarnak and Jaber2 reported that pulmonary infectious
mortality rates are 14–16 times higher in dialysis patients
than in the general population. In our study, the in-hospital
mortality rate for hemodialysis patients with a discharge
diagnosis of pneumonia was similar to the in-hospital
mortality of 11% found in a study of the general US
Medicare population14 and a general population study from
Canada.15 We found that all-cause mortality was higher than
expected after an episode of pneumonia, especially in the first
year. Throughout the 8 years of follow-up, the risk of death
remained approximately twice as high in patients who had an
episode of pneumonia, compared with those who did not.
The association between hospitalization with pneumonia and
long-term mortality has been seen repeatedly in the general
population, albeit with considerably better post-event
survival estimates.12,14,16
Our study has limitations. It is a retrospective observa-
tional study, and pneumonia was identified based on
administrative claims; no individual chart review was
possible. A single, a priori definition of pneumonia was not
applied prospectively in real time. A substantial number of
pneumonia cases likely occurred after admission to hospital
with another serious illness; in this scenario, an association
between pneumonia and mortality could reflect the occur-
rence of this other serious illness, without a direct causal link
between pneumonia and death. Our study involved a
Table 2 | Microbiologic spectrum among index pneumonia
hospitalizations (n=3101)
Organism Percent
No. of organism identified 81.8
Gram-positive bacteria 4.8
Streptococcus pneumoniae 3.4
Other Streptococcus species 1.0
Staphylococcus species 0.4
Gram-negative bacteria 11.1
Pseudomonas aeruginosa 2.8
Hemophilus influenzae 1.5
Klebsiella pneumoniae 1.6
Escherichia coli 0.7
Other Gram-negative organisms 4.5
Anaerobic bacteria 0.03
Atypical bacterium: Mycoplasma pneumoniae 0.3
Viral 1.0
Fungal 1.0
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Figure 2 | Kaplan–Meier estimates of survival probabilities
after pneumonia in non-waitlisted (solid line) and waitlisted
(dashed line) ESRD patients (Po0.0001 for non-waitlisted
vs waitlisted).
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Figure 3 | Adjusted mortality hazards ratios (with 95% CIs) from
Poisson regression analysis, in 6-month intervals. Adjustment was
made for each of the covariates shown in Table 1. In the first interval,
death rates in patients who developed pneumonia are compared
with death rates in those without pneumonia. In the second interval,
death rates of the combined group of patients who survived
pneumonia in the first interval and those who developed pneumonia
in the second interval are compared with death rates of patients who
remained pneumonia free. This process was continued, so that in the
nth interval, death rates of patients who developed pneumonia and
survived the preceding intervals, as well as those who developed
pneumonia in nth interval, are compared with death rates in patients
who remained pneumonia free.
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Figure 4 | Adjusted mortality hazards ratios (with 95% CIs) from
Poisson regression analysis limited to the 1199 patients on the
transplant waiting list, in 6-month intervals. Adjustment was
made for each of the covariates shown in Table 1. In the first
interval, death rates in patients who developed pneumonia are
compared with death rates in those without pneumonia. In the
second interval, death rates of the combined group of patients
who survived pneumonia in the first interval and those who
developed pneumonia in the second interval are compared with
death rates of patients who remained pneumonia free. This
process was continued, so that in the nth interval, death rates of
patients who developed pneumonia and survived the preceding
intervals, as well as those who developed pneumonia in nth
interval, are compared with death rates in patients who remained
pneumonia free.
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prevalent cohort of hemodialysis patients; therefore, patients
were not studied at a uniform phase of their chronic kidney
disease. Pertinent medication data were not readily available,
and biochemical data sets were incomplete. In hindsight, it
would have been attractive to make accurate assessments of
inflammatory, nutritional, and redox status. Unfortunately,
no biological samples were stored as part of the study. Finally,
the study population was assembled more than 10 years ago,
leading to a natural tension between the competing wishes
for longer follow-up, higher event rates, and greater statistical
power, on the one hand, and generalizability to latter-day
hemodialysis populations on the other.
Despite its limitations, our study may have practical
implications. Both the burden of disease and the associated
mortality associations were noteworthy. These findings might
encourage the use of preventive measures, timely diagnosis of
pneumonia, and prompt initiation of appropriate treatment.
For example, a national surveillance study of dialysis-
associated diseases in 2000 showed that only 64% of US
dialysis patients were vaccinated for influenza and 27% for
pneumococcal disease.17 The current study suggests that the
contribution of pneumonia to the morbidity and mortality
of dialysis populations may not have received the notice
it warrants. Prospective mechanistic, observational, and
therapeutic research is greatly needed in this population.
MATERIALS AND METHODS
Patients and measurements
For our final sample size of 10 635, we used USRDS standard
analysis files (WAITSEQ_KI, WAITSEQ_KP) derived from the
United Network for Organ Sharing kidney and kidney/pancreas
waitlist file to determine whether patients had been placed on the
transplant waiting list before the study start date. Pneumococcal
immunization within 5 years and influenza immunization between
September 1, 1993 and December 31, 1993 were determined from
Part A Medicare in-patient claims and Part B Medicare outpatient
claims using Current Procedure Terminology Codes 90655 to 90660,
90724, and G0008 for influenza vaccination, and 90669, 90732,
J6065, and G0009 for pneumococcal vaccination. Medicare coverage
in the hemodialysis population typically begins in the first year of
dialysis therapy or after age 65 years, and most guidelines suggest
that high-risk patients should receive pneumococcal vaccination
every 5–10 years. Hence, we could not reliably assess appropriateness
of pneumococcal vaccination in most patients, and pneumococcal
vaccination was not used as an exploratory variable in outcome
analyses.
Outcomes
The occurrence of pneumonia was determined from Part A
Medicare in-patient claims, using the following International
Classification of Diseases, Ninth Revision, Clinical Modification codes:
(1) viral pneumonia, 480.x. and 484.1; (2) pneumococcal pneumo-
nia 481; (3) other bacterial pneumonia 482.xx and 483.x; (4) fungal
pneumonia 112.4, 114.0, 115.xx, 484.6, 484.7; (5) pneumonia caused
by other or unspecified organisms 482.89, 482.9, 483.8, 484.3, 484.5,
484.8, 485, and 486. We defined our main outcome of pneumonia as
presence of one of these diagnostic codes for any of the discharge
diagnoses. Pneumonia was defined as the primary diagnosis for the
hospitalization if a Medicare claim specified it as the first discharge
diagnosis. Dates of death and transplantation were obtained from
the USRDS Patients File. Follow-up extended to December 31, 2001.
Analysis
The continuous variables age, duration of renal replacement therapy,
body mass index, and Kt/V were broken into categories commonly
used in other studies. The continuous variables serum levels of
albumin, hemoglobin, creatinine, and cholesterol were considered as
quintiles. Missing values were treated as separate categories.
Kaplan–Meier analysis was used to measure cumulative event-
free survival times for the following: first pneumonia hospitaliza-
tion, death in the overall population, and death after hospitalization
with pneumonia. Cox regression was used to identify antecedent
associations of hospitalization with pneumonia; three types of
analyses were performed, one that censored at transplantation, one
that did not censor at transplantation, and one that treated
transplantation as a time-dependent covariate. Findings were similar
with all three methods; only the findings using the last method are
presented here. Initial Cox models evaluating the association
between pneumonia and mortality showed substantial violation of
the assumption of constant hazards ratios over time; instead, we
used interval Poisson analysis, both censored and uncensored at
transplantation, to evaluate the association between hospitalization
with pneumonia and mortality. Because the findings were similar,
only the findings from the uncensored model are presented here.
All outcome analyses were repeated in the subset of patients
waitlisted for transplantation before the study start date, and were
performed using SAS for Windows, version 8.2 (SAS Institute, Cary,
NC, USA).
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